Interleukin-2 therapy in patients with HIV infection

New England Journal of Medicine

Volumn 362, Issue 3, 2010, Pages 270-271

  Sellier, Pierre ^a   Lafuente Lafuente, Carmelo ^a   Bergmann, Jean François ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 74849114986     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0910951     Document Type: Letter

References (6)

1. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59.
2. Girardi E, Sabin C, Monforte A. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46:Suppl 1:S3-S8.
3. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The Moralité 2000 and 2005 surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48:590-8.
4. Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007;12:89-96.
5. Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9.
6. Tincati C, Meroni L, Bellistri G, et al. Effects of immunoad-juvant therapy with IL-2 in HIV-positive HAART-naive patients in advanced stage of disease: a characterization of the diverse immunological responses to IL-2. Presented at the 11th European AIDS Conference/European AIDS Clinical Society, Madrid, October 24-27, 2007.